STOCK TITAN

Inogen, Inc. - $INGN STOCK NEWS

Welcome to our dedicated page for Inogen news (Ticker: $INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inogen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inogen's position in the market.

Rhea-AI Summary

Inogen, Inc. (Nasdaq: INGN) announced their first quarter 2024 financial results, showing an 8.1% increase in total revenue to $78.0 million, accompanied by a total gross margin of 44.1%. The GAAP net loss was $14.6 million, with adjusted net loss at $10.4 million. Adjusted EBITDA was a negative $7.6 million. Inogen expects revenue for the second quarter of 2024 to be in the range of $81 million to $84 million. The company remains focused on revenue growth, profitability, and innovation to enhance their market position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.88%
Tags
-
Rhea-AI Summary
Inogen, Inc. (INGN) will report its first quarter 2024 financial results on May 7, 2024, followed by a conference call. The call will be accessible via phone and webcast. The company emphasizes transparency by archiving the call and providing a replay option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags
conferences earnings
-
Rhea-AI Summary
Inogen, Inc. (INGN) to participate in the 23rd Annual Needham Virtual Healthcare Conference. Kevin Smith and Michael Bourque to discuss innovative respiratory products. Webcast available for interested parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
conferences
Rhea-AI Summary
Inogen, Inc. announced the approval of restricted stock units as a material inducement for Michael Bourque, the new Executive Vice President, Chief Financial Officer, and Treasurer. The equity awards consist of 75,000 time-based RSUs and 75,000 performance-based PSUs, potentially reaching a maximum of 150,000 PSUs. The awards are subject to vesting based on Mr. Bourque's continued service and Inogen's performance goals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
none
-
Rhea-AI Summary
Inogen, Inc. (INGN) reported fourth-quarter 2023 revenue of $75.9 million and full-year 2023 revenue of $315.7 million. The company highlighted a focus on revenue growth, profitability, and innovation in 2024. Notable financial results included a decrease in total revenue due to lower business-to-business and direct-to-consumer sales, offset by higher rental revenue. The company reported a GAAP net loss of $26.6 million for Q4 2023 and $102.4 million for full-year 2023. Adjusted net loss was $19.4 million for Q4 2023 and $48.3 million for full-year 2023. Inogen expects first-quarter 2024 revenue of $73 to $74 million, representing 1% to 3% growth compared to Q1 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.66%
Tags
-
Rhea-AI Summary
Inogen, Inc. (INGN) will report Q4 and full year 2023 financial results on February 27, 2024. A conference call and webcast will be hosted the same day. The call will be accessible through dial-in and webcast, with a replay available for three hours after the live webcast ends. Inogen uses its Investor Relations website to disclose material non-public information and comply with disclosure obligations under Regulation FD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.31%
Tags
conferences earnings
Rhea-AI Summary
Inogen, Inc. (Nasdaq: INGN) has appointed Michael Bourque as the new Chief Financial Officer, effective March 4, 2024. Bourque brings extensive experience from his roles at Chase Corporation, Keystone Dental, Analogic Corporation, and Axcelis Technologies. Inogen's President and CEO, Kevin Smith, expressed excitement over Bourque's appointment, highlighting his ability to help the company continue delivering superior respiratory solutions. The former Interim CFO, Mike Sergesketter, will remain in an advisory role during the transition. Bourque's appointment marks a pivotal point in Inogen's story, with a focus on delivering value to patients and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
none
-
Rhea-AI Summary
Inogen, Inc. (NASDAQ: INGN) appoints Kevin Smith as President and CEO, bringing over 20 years of medical device industry experience, aiming to drive growth and organizational transformation. The company reaffirms its full year financial guidance and announces its non-attendance at upcoming healthcare conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
management
-
Rhea-AI Summary
Inogen, Inc. (INGN) to present at Stifel 2023 Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference. The live webcast will be available on the Inogen Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.68%
Tags
conferences
Rhea-AI Summary
Inogen, Inc. (Nasdaq: INGN) Announces Q3 2023 Financial Results, Reports $84.0 Million in Total Revenue, a 20.3% Decrease from Q3 2022
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
Inogen, Inc.

Nasdaq:INGN

INGN Rankings

INGN Stock Data

202.76M
21.19M
0.92%
93.79%
7.23%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
GOLETA

About INGN

inogen’s mission to improve the quality of life of supplemental oxygen users began in 2001 when mae, a beloved grandmother, was prescribed oxygen therapy. learn more about mae’s story here: http://www.inogen.com/about-inogen/meet-mae/. inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. we estimate that more than 2.5 million patients in the united states and more than 4.5 million patients worldwide use oxygen therapy. our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. we believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. with each step we take to improve our products and service, our customers take